DFTX logo

DFTX
Definium Therapeutics Inc.

25,822
Mkt Cap
$2.06B
Volume
500,299.00
52W High
$21.10
52W Low
$4.70
PE Ratio
-9.99
DFTX Fundamentals
Price
$20.27
Prev Close
$20.68
Open
$20.62
50D MA
$17.70
Beta
1.78
Avg. Volume
1.79M
EPS (Annual)
-$2.06
P/B
6.15
Rev/Employee
$0.00
$825.08
Loading...
Loading...
News
all
press releases
Definium Therapeutics, Inc. (NASDAQ:DFTX) Given Average Rating of "Buy" by Analysts
Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) has been assigned a consensus rating of "Buy" from the twelve brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and two hav...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Definium Therapeutics (NASDAQ:DFTX) Sets New 52-Week High - Here's Why
Definium Therapeutics (NASDAQ:DFTX) Hits New 52-Week High - Still a Buy...
MarketBeat·5d ago
News Placeholder
Definium Therapeutics, Inc. (NASDAQ:DFTX) Short Interest Update
Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) was the target of a large decline in short interest in March. As of March 13th, there was short interest totaling 15,008,738 shares, a...
MarketBeat·8d ago
News Placeholder
Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026
Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced additional details for its Investor & Analyst Day in New York on...
Business Wire·11d ago
News Placeholder
Definium Therapeutics (NASDAQ:DFTX) Sets New 12-Month High - Here's Why
Definium Therapeutics (NASDAQ:DFTX) Hits New 1-Year High - Here's Why...
MarketBeat·17d ago
News Placeholder
Definium Therapeutics Teases 3 Key DT-120 Data Readouts This Year, Highlights De-Risked Phase 3 Design
Executives from Definium Therapeutics (NASDAQ:DFTX) outlined clinical, regulatory, and commercial priorities for its lead psychedelic-derived program during a management discussion, emphasizing multiple pivotal readouts expected later this year and a focus on trial design intended to address common...
MarketBeat·18d ago
News Placeholder
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names
Key PointsSuperstring Capital Management acquired 425,202 shares of Definium Therapeutics in the fourth quarter...
Nasdaq News: Markets·19d ago
News Placeholder
Boxer Capital Management LLC Takes Position in Definium Therapeutics, Inc. $DFTX
Boxer Capital Management LLC purchased a new position in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing...
MarketBeat·22d ago
News Placeholder
Definium Therapeutics Teases Phase III DT120 Data for Anxiety, Depression at Leerink Conference
Definium Therapeutics (NASDAQ:DFTX) outlined its clinical pipeline and upcoming data catalysts at the Leerink Partners Global Healthcare Conference, with CEO Robert Barrow and CFO Brandi Roberts...
MarketBeat·22d ago
News Placeholder
Commodore Capital LP Lowers Holdings in Definium Therapeutics, Inc. $DFTX
Commodore Capital LP lowered its stake in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX - Free Report) by 35.5% during the 3rd quarter, according to the company in its most recent Form 13F...
MarketBeat·22d ago
<
1
2
...
>

Latest DFTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.